BioMarin Pharmaceutical Inc. (BMRN) 2005年年度报告「NASDAQ」.pdf

1、 On May 31,2005,the U.S.Food and Drug Administration(FDA)approved NaglazymeTM(galsulfase),the first enzyme replacement therapy for the treatment of mucopolysacchari-dosis VI(MPS VI).This was the second time in BioMarins eight-year history that the company successfully advanced a product through the

2、clinic and into the marketplace.At BioMarin,we are committed to developing and com-mercializing innovative biopharmaceuticals for serious diseases and medical conditions.We are aggressive in this undertaking and seek product opportunities that suggest a clear development path,provide an opportunity

3、to be first to market and,most importantly,will address unmet medical needs.6R-BH4 for Cardiovascular IndicationsPhenoptin for PKUPhenylase for PKUNaglazyme for MPS VIPipelinePhase 1Phase 2Phase 3BLA/NDA/MAAAldurazyme for MPS IOrapred ODT for Inflammatory ConditionsOn The MarketPreclinicalBIOMARIN:M

4、ATCHING PROVEN SCIENCE WITH PROVEN NEEDS2005 was a year marked by significant growth and success for BioMarin:we increased net product sales of Aldurazyme(laronidase);we moved Naglazyme through clinical devel-opment to market;we advanced and added to our product pipeline;and we formed a strategic pa

5、rtnership that will help fund our lead clinical programs.We enter 2006 with continued resolve to build a sustainable biopharmaceutical company that will satisfy the interests of our stockholders and address unmet medical needs.Net product sales of Aldurazyme for mucopolysaccharidosis I(MPS I)by BioM

6、arin/Genzyme LLC continued to grow in 2005,increasing 79 percent in comparison to the previous year.In line with this,our share of the profit from this 50/50 joint venture grew to$11.8 million for the year.As we move forward in 2006,we expect to see increasing profits from Aldurazyme as product sale